Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Identifying the switches that turn cell growth off and on would have profound implications for cancer medicine. If the right mechanisms can be found, cancer cells could be targeted specifically, resulting in more efficient treatments. Nuclear reprogramming could also enable cells to be utilized more safely and effectively in regenerative medicine.

Q: What is the link between regenerative medicine and cancer?

XL: How to control cell growth in my view, is the underlying link between regenerative medicine and cancer. Cancer is a disease where the cancer cells grow uncontrollably and in the wrong place. Regenerative medicine, on the other hand, is trying to regenerate new cells to replace lost or damaged cells in the disease, for example neuro-degenerative disease.

Q: How can this knowledge improve the efficacy of cancer treatment?

XL: For us to treat cancer efficiently we need to understand how the cells grow uncontrollably. If we understand how the whole control process is governed, we will be able to stop the growth more efficiently and kill the cancer cells selectively and efficiently.

Q: What are the most important developments over the past 5 or 10 years?

XL: In my personal view, I think the understanding of how to reprogram cells through nuclear reprogramming is the most exciting and fascinating discovery in the last 5 or 10 years. What this means is that you can take a cell, add in four factors and you could change the cell fate. You can change the cell into a stem cell and then you can induce the cells into all sorts of types of cells. At the same time how to reprogram cells into all sorts of different fates is exactly what went wrong in cancer. One of the four factors that people use to reprogram a cell is also a factor that promotes cancer cell growth, we call it oncogene. The reprogramming process is actually not that efficient. The reason it is not so efficient is because there is a break built in our cells and we call it a tumour suppressor. This is what governs us not to get cancer at the very early stage.

Q: Why does your line of research matter? Why should we put money into it?

XL: What we do is to identify molecular switches that control cell growth. It also controls how the cell would change its fate. Therefore anything we identify clearly is critical both for regenerative medicine and cancer.

Q: How does your research fit into translational medicine within the department?

XL: If we identify the key molecular switches that are able to allow us to stop the cancer cell growth, or to kill the cancer cells selectively, that would undoubtedly enhance the cancer treatment efficacy. It could also have implications in the prevention of cancer development, provide biomarkers for early diagnoses of cancer, and also give you the prognosis for the cancer treatment. At the same time the same molecular switches we do believe would allow us to enhance the efficacy of reprogramming of cells for regenerative medicine, and most importantly to provide safe cells for regenerative medicine because one of the major challenges in regenerative medicine is that you can reprogram a cell but you might reprogram it into a cancer cell. You don't want to reprogram a cancer cell you want to reprogram a normal cell to replace what has been lost or damaged to give that treatment for the regenerative medicine.

Xin Lu

Tumour suppression

Professor Xin Lu is the Director of the Oxford branch of the Ludwig Institute for Cancer Research. Her lab works toward identifying molecular mechanisms that suppress tumour growth and metastasis, and focuses on understanding the factors that lead to uncontrollable cell growth.

More podcasts related to Cancer

Raghib Ali: INDOX Cancer Research Network

Cancer Ex-faculty podcasts Global Health

INDOX is a collaboration between Oxford and twelve leading cancer centres in India. It aims to develop effective and affordable cancer treatments in low and middle income countries, to improve the early detection of cancer, and to reduce the incidence of cancer by establishing the population specific risk factors.

Vincenzo Cerundolo: Cancer immunology

Cancer Ex-faculty podcasts

The development of therapeutic vaccines is more challenging. Current lines of research include the development of antibodies blocking inhibitory T cell signals, and the characterisation of adjuvants.

David Jackson: The Lymphatic System in Immunity and Cancer

Cancer Ex-faculty podcasts

Our lymphatic system protects us against pathogens: it collects micro-organisms and carries them to the lymph nodes where they will meet and activate T cells and B cells. Cancer cells also migrate to the lymph nodes, but instead of activating the immune system they actually suppress it. A better understanding of these mechanisms might help us better control the spread of tumours, and also block unwanted immune responses in autoimmune diseases, block tissue rejection and make vaccines more effective.

Tim Key: Role of Lifestyle and Diet in Cancer

Cancer Ex-faculty podcasts

We know that although smoking is still the most important cause of cancer, obesity and high intakes of alcohol increase the risk for several types of cancer. The role of diet in the development of cancer is much less clear, but there is a lot of evidence suggesting that diet does matter.

Patrick Pollard: Cancer Metabolism

Cancer Ex-faculty podcasts

Dr Pollard’s work is focused on a form of kidney cancer for which no effective therapy exists once it metastasizes. By integrating analyses of these cancer cells and novel models he hopes to provide insights into altered cancer metabolism and a real, innovative route into the design of therapies for various cancers.

Catherine Green: DNA replication and Cancer

Cancer Genetics

The process of DNA replication is complex, and mistakes can lead to genome instability. Surveillance systems are not always successful which results in mutations that have the potential to inactivate genes or change their activity. This can lead to cancer, and many chemotherapeutic drugs are designed to disrupt DNA replication. A better understanding of these mechanisms can help us develop new drugs with reduced side effects.

Skirmantas Kriaucionis: Epigenetic modifications and cancer

Cancer

Although all cells in our body have the same genome, they look different and perform different functions. Epigenetic modifications such as methylations ensure which sets of genes are expressed in specific cells and how this specificity is inherited. Cancer cells show particular epigenetic abnormalities which can be targeted for cancer therapies.

Ross Chapman: Repairing DNA damage

Cancer

Whilst controlled DNA breaks allow for our vast repertoire of antibodies, DNA damage happening out of context can lead to cancer or predisposition to cancer. Recent developments in personalised medicine exploit the DNA repair weaknesses of cancer cells to selectively kill them. A better understanding of the underlying mechanisms can help develop innovative and targeted therapies.

John Christianson: Cleaning up misfolded proteins

Cancer

Misfolded proteins can either create the loss of a cellular function, or escape degradation, causing aggregation diseases. Better knowledge of these mechanisms helps us understand the root cause of different kind of diseases, and also develop targets for therapeutic intervention.

Robert Gilbert: Targeting cancer mechanisms

Cancer

Switching mechanisms within our cells are in part responsible for their development. MicroRNAs control a whole set of proteins associated with stem cell biology, particularly cancer stem cells. Targeting these components raises the potential for new anti-cancer therapeutics, which work by switching off protein production rather than inhibiting them later.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.